check_circleStudy Completed

Contraception

Bayer Identifier:

91309

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-002967-26

EU CT Number:

Not Available
Gravistat 125 Bioequivalenz

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
42
Trial Dates
April 2005 - September 2005
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Estradiol Valerate (EV, DS00124)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, crossover study to investigate the bioequivalence of two different tablet formulations containing 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel (with gelatin [SH D00342E] versus gelatin-free [SH D00342D]) and to compare the bioavailability of the gelatin-containing formulation to that of a microcrystalline suspension [SH M00342C] in healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.